Abstract
Although epilepsy is one of the most common neurologic disorders, there is still a lack of effective therapeutic drugs for it. Recently, we synthesized a novel hydrogen sulfide (H2S) donor, which is found to reduce seizures in animal models effectively. But it remains to be determined for its mechanism. In the present study, we found that the novel H2S donor could reduce pilocarpine-induced seizures in mice. It alleviated the epileptic behavior, the hippocampal electroencephalography (EEG) activity of seizures, and the damage of hippocampal neurons in status epilepticus mice. In addition, the novel H2S donor could reduce microglial inflammatory response. It not only reduced the upregulation of pro-inflammatory markers [inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2)] in status epilepticus mice, but also increased the levels of microglial anti-inflammatory marker arginase-1 (Arg-1). In lipopolysaccharide-treated microglia BV2 cells, administration of the H2S donor also significantly reduced the lipopolysaccharide-induced upregulation of the expression of the pro-inflammatory markers and increased the expression of the anti-inflammatory markers. Thus, the novel H2S donor regulates microglial inflammatory profile in status epilepticus mice and in vitro. These results suggested that the novel H2S donor can reduce seizures and regulate microglial inflammatory profile, which may be a novel mechanism and potential therapeutic strategy of the H2S donor anti-seizures.
Introduction
Epilepsy, a nervous system disorder characterized by sudden abnormal hypersynchrony of neurons, affects 70 million people in the world. Despite there are various antiepileptic drugs available, approximately 30–40% of patients are refractory to these treatments (; ). Therefore, it is urgent to explore the pathogenesis of epilepsy and find alternative treatment strategies.
Microglia are brain resident immune cells and are emerging as central players in regulating pathways of central nervous system (). Microglia are phenotypic plastics and can be activated by variety of stimuli to express various inflammatory profile (; ). In some specific disease states, microglia express more inducible nitric oxide synthase (iNOS) and release more pro-inflammatory cytokine including interleukin (IL)-1β and tumor necrosis factor-α (TNF-α). While under the stimulation of specific drugs or cytokines (such as resveratrol or IL-4), the expression of several proteins including arginase-1 (Arg1) and the production of anti-inflammatory cytokines such as IL-10, IL-4, and IL-13 increased in microglia (; ; ; ; ). A number of studies have reported that microglial activation was observed in patients and animal models of various types of epilepsy (; , ). Microglial activation has been recognized as a major contributor to inflammation of the epileptic brain (). The “activated” microglia have exhibited heterogeneity in their phenotypes, which makes it difficult to determine whether these microglia are proepileptic or antiepileptic (). Both microglial pro-inflammatory cytokines (IL-1β and TNF-α) and anti-inflammatory cytokines (IL-4 and IL-10) showed increased expression after pilocarpine-induced status epilepticus, indicating a complex role of microglia in the epileptic brain (). Microglial pro-inflammatory cytokines have been implicated in epileptogenesis. In contrast, microglial anti-inflammatory cytokines participate in the resolution of the inflammatory processes, thereby potentially limiting epileptogenesis (; ). Therefore, modulation of microglial inflammatory profile will become a potential therapeutic strategy for epilepsy.
Hydrogen sulfide (H2S), a traditional toxic gas in the atmosphere, is synthesized endogenously in mammals and recognized as a gaseous signaling molecule that may act as a neurotransmitter in brain (; ; ; ). Concentrations of H2S in the brain changes in a variety of neurological diseases including seizures (; ; ; ; ). High concentration of H2S has toxic effects, whereas low concentration of H2S has neuroprotective effects (; ). The downregulation of H2S levels results in hippocampal hyperactivity in febrile seizure rats, whereas neural excitability is reduced by administration of NaHS (). H2S can also prevent damage in the hippocampus caused by recurrent episodes of febrile seizures (). Unfortunately, traditional H2S donors including NaHS and other sulfates are easily oxidized to form sulfane sulfursor and cause adverse effects due to quick release (). Recently, we synthesized a novel carbazole-based H2S donor, which is safer and has more effective pharmacological administration to release H2S (; ; ; ). We found that the novel H2S donor has the effects of neuroprotection and reduction of epileptic seizures (, ; ). However, the underlying mechanisms of the H2S donor against seizures are poorly understood. In this study, we investigated the potential role of the novel H2S donor in regulating microglial inflammatory profile and found that it can decrease microglial pro-inflammatory profile and simultaneously increase the microglial anti-inflammatory profile in pilocarpine-induced status epilepticus mice.
Materials and Methods
Animals
Adult male C57BL/6 mice (25 ± 2g, 8–12 weeks old) were purchased from GemPharmatech conditions (ambient temperature: 20 ± 2°C; humidity: 60 ± 5%) with 12 h light/dark cycle, and provided ad libitum access to food and water. All mice were randomly divided into four groups: Control group (Ctrl), SE group, H2S donor intervention group (SE+H2S), and H2S donor control group (H2S).
Initially, the mice were pretreated with H2S donor or dimethyl sulfoxide (DMSO) 2 h before pilocarpine-induced status epilepticus (SE). Then, the behavioral changes and electroencephalography (EEG) of mice were recorded during SE. The mice were sacrificed at various time points (1d, 7d, 14d, 28d) after the SE induction, and the brain was removed and stored at −80°C for corresponding experiments. All the experiments were approved by the Institutional Animal Care and Use Committee of Guangzhou Medical University.
Pilocarpine-Induced Status Epilepticus Model
After pretreatment with H2S donor (500 μM, 5 μl, i.c.v.) or DMSO (5 μl, i.c.v., sigma, United States) for 2 h, animals from both groups (SE and SE+H2S) were injected with pilocarpine to induce SE. Specifically, atropine (1 mg/kg, i.p., sigma, United States) was given 30 min prior to pilocarpine hydrochloride (300 mg/kg, i.p. of meilinbio, China) to reduce the peripheral effects. Seizure scores were assessed according to the protocol of a previous study (). Briefly, some mice presented a generalized convulsive (stage 4 or 5) seizure that turned into continuous seizures in the form of limbic motor seizures with intense salivation, rearing, upper extremity clonus, and falling, lasting up to 90–150 min, which characterized SE. Diazepam (10 mg/kg, i.p., King York, China) was injected 90 min after SE onset to inhibit or alleviate SE. The mice that progressed to at least Stage 4 were killed for immunohistochemistry or western blot at various time points.
H2S Donor Pretreatment by Lateral Ventricle Injection
The mice were anesthetized by intraperitoneal injection of 2% sodium pentobarbital, and then fixed on the stereotactic apparatus. The H2S donor was delivered at 500 μM in 5 μl of DMSO in mice by i.c.v. injection. The coordinates were as follows: 0.2 mm posterior to bregma, 0.9 mm lateral to the sagittal suture, and 2.0 mm below the subdural surface (; ). The needle was remained in place for 10 min and then withdrawn slowly.
Electroencephalography
Hippocampus EEG was recorded as previously described (). First, the mice were anesthetized by intraperitoneal injection of 2% sodium pentobarbital (30 mg/kg) and fixed in the stereotactic apparatus. The hippocampus was located as follows: 2.3 mm posterior to bregma, 1.8 mm lateral, 2.0 mm ventral to the duramater. The skull was drilled, and a stainless steel bipolar copper core electrode was inserted into the subdural 3.0 mm. After implantation, all electrostatic electrodes were fixed on the skull with jewel screws and dental acrylic acid. EEGs of mice were recorded by a BL-420E Biological Function Experimental System (Techman, Chengdu, China) for 1 h. Then, the wave amplitudes were measured in microvolts (μV) via TM_WAVE version 2.1 (Techman, Chengdu, China) and data were analyzed and counted.
Western Blotting
The hippocampal tissue or BV2 cells were lysed with radio immunoprecipitation assay (RIPA) lysate (Beyotime, China). The protein concentration was measured by bicinchoninic acid (BCA) Protein Assay Kit (Beyotime, China). Due to the difference in the expression of target proteins (such as IL-10 and Arg-1), the loading mass of total protein was increased up to 80 μg per lane in order to obtain clearer band signals. The total loading volume is controlled within 10 μl per lane to avoid sample overflow. Samples were subjected to 10–12% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel electrophoresis and transferred onto polyvinylidene-difluoride (PVDF, Millipore, United States) membranes. Then, the membranes were blocked with bovine serum albumin (BSA), and incubated with rabbit anti-COX2 (1:500, #12375-1-AP, Proteintech Group, United States), rabbit anti-Arg-1 (1:4,000, #16001-1-AP, Proteintech Group, United States), rabbit anti-TNF-α (1:1,000, #bs-0078R, BIOSS, China), rabbit anti-IL-10 (1:1,000, #bs-20373R, BIOSS, China), mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:8,000, #60004-1-Ig, Proteintech Group, United States), and rabbit anti-Tubulin (1:1,000, #11224-1-AP, Proteintech Group, United States) at 4°C overnight. After that, the protein strips were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature for 1h, and analyzed with the Bio-Rad ChemiDoc Imaging System. Bands densities were digitally quantified by Image J software.
Nissl Staining
The hippocampal tissue sections were mounted and were dehydrated in ascending series of ethanol. Then, the slices were stained with Nissl Staining Solution (Beyotime, China). Finally, the slices were observed under a microscope. At least three sections were taken from each brain. And, all assessments of histological sections were performed blindly.
Immunohistochemistry and Immunofluorecent
After blocking with QuickBlock Blocking Buffer for Immunol Staining (Beyotime, China), the slices of cells or tissue were incubated with the corresponding primary antibody for goat anti-Iba1 (1:200, #ab5076, Abcam, United Kingdom), mouse anti-iNOS (1:200, # sc-7271, Santa Cruz Biotechnology, United States), or rabbit anti-Arg-1 (1:100, #16001-1-AP, Proteintech Group, United States) overnight at 4°C, and then were incubated with the second antibody (1:500, AlexaFluor-594 and/or 1:500, AlexaFluor-488, Multisciences, China) at 37°C for 1 h. After three washes with phosphate-buffered saline (PBS) for 5 min each, 2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI) was added to stain nuclei for 5 min. And images were scanned under a confocal laser-scanning microscope (SP8; Leica). Cell numbers were calculated by counting per random microscopic field via a blind method. The data are expressed as the number of Iba1+ cells per field or the percentage of iNOS+ or Arg-1+ cells in Iba1+ cells. Cell fluorescent signal intensity was quantified using Image J.
Cell Culture and Model of Inflammation in vitro
BV2 cells were purchased from American Type Culture Collection (Manassas, VA, ATCC) and were cultured in Dulbecco’s modified eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) at 37°C in a humidified incubator with 5% CO2. The cells were treated with H2S donor (100 μM) for 12 h before being treated with 100 ng/ml lipopolysaccharide (LPS, Escherichia coli serotype 055:B5, sigma, United States) for another 12 h ().
Statistical Analysis
These results were obtained through more than three independent repeated experiments. Data were analyzed using statistical product and service solutions (SPSS) 25.0 software (SPSS Inc., Chicago, IL, United States) and one-way or two-way ANOVAs, followed by Bonferroni’s post hoc test. All data were expressed as the mean ± SEM, and the statistical significance level was set at p < 0.05.
Results
The H2S Donor Reduced Seizures in Pilocarpine-Induced Status Epilepticus Mice
To investigate the effect of the novel H2S donor on seizures, we performed i.c.v injection of the H2S donor (500 μM, 5 μl) in pilocarpine-induced SE mice. First, the severity of seizures was observed by testing Racine scale. As shown in Figures 1A,B, the control group mice did not appear epileptic seizure. The SE mice treated with the H2S donor displayed a longer latency of seizure onset (ANOVA, p = 0.001) and a shorter seizure duration (ANOVA, p < 0.001) than pilocarpine-induced SE mice. Meanwhile, EEG was applied to record the brain waves of the hippocampus of mice. As shown in Figure 1C, no abnormal discharge was observed in mice of the control group. EEG traces in SE mice showed epileptic brain waves characterized by sharp, spiking, or spiking/slow waves. Consistent with the behavioral observation, administration of the H2S donor significantly reduced the epileptic waves (Figure 1C). EEG amplitude analysis in Figure 1D showed that wave amplitudes in SE mice were significantly higher than (ANOVA, p < 0.001) that in control mice. And the H2S donor decreased the amplitudes of epileptic wave in SE mice (ANOVA, p < 0.001) (Figure 1D). These results suggested that the H2S donor reduced seizures in pilocarpine-induced mice model.
FIGURE 1
The H2S Donor Reduced Neuronal Damage in the Hippocampus of Status Epilepticus Mice
Next, we investigated the effect of the novel H2S donor on the neuronal damage in different periods after status epilepticus by Nissl staining. At the early stage (1d) after status epilepticus, both CA3 and CA1 areas of the hippocampus showed pyramidal cells arranged densely in line. The Nissl bodies were stained bluish violet and evenly distributed in the cytoplasm, suggesting no obvious morphological damage occurred in the early stage (Figures 2A,B). However, the visible decrease of Nissl bodies occurred at 7d after status epilepticus, reached a peak at 14d, and repaired at 28d. In SE mice, disorder of neuronal arrangement and central chromatolysis were observed in both CA3 and CA1 regions of the hippocampus in progressive stage (7d and 14d). In the convalescent/chronic stage (28d), Nissl body in the cytoplasm partly recovered, and necrosis of neurons were replaced by vacuoles like structures in the tissues (Figures 2A,B). However, SE mice treated with the novel H2S donor displayed a better morphology of neurons and more Nissl bodies in cytoplasm in the hippocampus, compared with SE mice. Even on the 14th day of the most severe seizures injury, the complete cell contour was preserved in the H2S donor-treated SE mice, but not in SE mice. In convalescent/chronic stage after status epilepticus, there are more dense Nissl bodies and fewer vacuolar structures in the cytoplasm in the hippocampus of the H2S donor-treated SE mice. These results suggested that the H2S donor decreased the damage of hippocampal neurons in progressive stage of status epilepticus and promoted the repair of neuronal injury in chronic stage.
FIGURE 2
The H2S Donor Downregulated the Levels of Microglial Pro-inflammatory Profile in vivo
Microglial activation has been recognized as a major contributor to inflammation of the epileptic brain (). We explored the role of the novel H2S donor on the inflammatory profile regulation of microglia. A few Iba1+cells stained with green were observed in the hippocampus of the control and the H2S donor-treated group. These Iba1+cells have small cell bodies with a few bifurcations. And there was no significant difference between the two groups in appearance (data not shown). As shown in Figures 3A–D, a number of Iba1+cells with different morphologies were observed in the hippocampus of each group. These Iba1+cells in SE groups more likely had an enlarged and flat shape cell body with amoeboid appearance. However, in the H2S donor-treated SE groups, Iba1+cells did not show the inflammatory activation state and showed multi-bifurcated appearance. We quantified the number of Iba1+ cells in each group and found that there were more Iba1+cells in SE groups [two way-ANOVA, CA1: F(1, 36) = 17.37, p < 0.001; CA3: F(1, 36) = 44.79, p < 0.001] (Figure 3E). The number of Iba1+cells in both the CA1 and CA3 areas of the hippocampus increased to a peak at 14 d after status epilepticus [two way-ANOVA, CA1: F(2, 36) = 13.72, p < 0.001; CA3: F(2, 36) = 25.30, p < 0.001] and declined by 28 d [two way-ANOVA, CA1: F(2, 36) = 13.72, p < 0.001; CA3: F(2, 36) = 25.30, p < 0.001] after pilocarpine. We also observed iNOS, a pro-inflammatory marker, co-localized with Iba1. The number of iNOS/Iba1 double-labeled cells was significantly more in SE mice than that in the H2S donor-treated SE mice [two way-ANOVA, CA1: F(1, 36) = 91.38, p < 0.001; CA3: F(1, 36) = 64.56, p < 0.001] (Figure 3F). In contrast, the co-localized cells of the anti-inflammatory marker Arg1/Iba1 were fewer in SE mice than that in the H2S donor-treated SE mice [two way-ANOVA, CA1: F(1, 36) = 184.28, p < 0.001; CA3: F(1, 36) = 153.95, p < 0.001) (Figure 3G). The Western blot assay showed that the H2S donor treatment alone did not increase the expression of inflammatory profile (such as TNF-α, COX2, IL-10, and Arg1) (Figures 3H–K). However, the H2S donor treatment in SE mice not only decreased the expression of microglial pro-inflammatory markers (COX2 and TNF-α) in the hippocampus (ANOVA, COX2: p = 0.03; TNF-α: p = 0.01) (Figures 3H,J), but also increased the levels of microglial anti-inflammatory markers (Arg1 and IL-10) (ANOVA, Arg1: p = 0.002; IL-10: p = 0.009) (Figures 3I,K). Taken together, our results indicate that the novel H2S donor reduced microglial pro-inflammatory profiles and promoted the anti-inflammatory profiles in the pilocarpine-induced SE mice.
FIGURE 3
The H2S Donor Downregulated the Levels of Microglial Pro-inflammatory Profile in vitro
To further clarify the effect of the H2S donor on the inflammatory profile of microglia, we established an inflammation model of microglia induced by LPS in BV2 cells. LPS can result in microglia activation and increase pro-inflammatory cytokines, which is thus known as a representative microglial activation inducer (). As shown in Figures 4A–C,E, LPS significantly increased the pro-inflammatory marker iNOS expression in BV2 cells with no change in the anti-inflammatory marker Arg1 expression. The increased iNOS expression was significantly reduced by administration of the H2S donor in LPS-treated BV2 cells (ANOVA, p < 0.001). In contrast, the H2S donor had an upregulating effect on Arg1 expression (ANOVA, p = 0.04). The Western blot assay shows that LPS caused an increase in the expression of the pro-inflammatory markers (COX2 and TNF-α) in BV2 cells (ANOVA, COX2: p = 0.001; TNF-α: p = 0.008), but not in that of the anti-inflammatory markers (Arg1 and IL10) (Figures 4D,F). Administration of the H2S donor significantly reduced the LPS-induced upregulation of the expression of the pro-inflammatory markers (ANOVA, COX2: p = 0.004; TNF-α: p = 0.02) (Figure 4D), and increased the expression of the anti-inflammatory markers in LPS-treated BV2 cells (ANOVA, Arg1: p = 0.03; IL10: p = 0.04) (Figure 4F). These results suggested that the H2S donor had also regulating effect on inflammatory profile in LPS-induced inflammation model of microglia in BV2 cells.
FIGURE 4
Discussion
Hydrogen sulfide has been identified as an important endogenous gasotransmitter regulating various physiological and pathological processes. Recently, we synthesized a novel more stable H2S donor, and found it has inhibitory effects on epileptic seizures in a pentetrazol (PTZ)-induced rat model (, ). The present study indicated that the novel H2S donor also reduced seizures in pilocarpine-induced mice model. The novel H2S donor could prolong the latency to seizure onset, and shorten the duration of seizures. In addition, the H2S donor could downregulate the levels of microglial pro-inflammatory profile and increase the levels of microglial anti-inflammatory profile in vivo and in vitro.
Inflammatory cytokines play an important role in epileptic seizure (; ). The levels of several pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α are often elevated in cerebrospinal fluid and serum of patients or rats with epilepsy (; ). These cytokines can increase the excitability of neurons and damage neurons, and are thus thought to be involved in epileptogenesis (, ). Therefore, anti-inflammatory therapy can effectively reduce the occurrence of epilepsy and chronic seizures. Anti-inflammatory cytokines such as IL-10 may potentially limit epileptogenesis. Both in vitro and in vivo studies show that H2S has regulating effects on various inflammatory factors (; ; ). For example, the H2S donor (NaHS) administration reduced the expression of microglial pro-inflammatory markers (IL-1β and TNF-α) and concomitantly increased the expression of microglial anti-inflammatory profile (IL-4 and TGF-β) in the brain regions of LPS-treated animals (). However, the H2S administration alone had no effect on basal inflammatory markers (such as COX2, TNF-α, IL-10, and IL-4) (; ). Consistent with the present results, the H2S donor by itself does not decrease the basal level of TNF-α or IL-10. Thus, the H2S only has effects on the changes of inflammatory factors in the disease states, and does not change their basic levels. Besides, the present study also showed that the novel H2S donor pretreatment can not only decrease the levels of TNF-α, but also markedly increase the levels of IL-10 in the hippocampus of SE mice. Consistently, morphological observation showed that the H2S donor decreased the damage of hippocampal neurons in progressive stage of status epilepticus and promoted the repair of neuronal injury in chronic stage. EEG recordings showed that the H2S donor reduced the hippocampal epileptic waves and EEG amplitude. Obviously, the present results of the three effects of the H2S donor on the hippocampus are consistent in SE mice.
The microglia are privileged with phenotypic plasticity and can be stimulated by different stimuli to regulate physiological responses and behavioral results in disease (). It is widely accepted that microglial activation occurs following seizures (; ). The activated microglia play a primary role in the production of cytokines. The expression levels of microglial pro-inflammatory cytokines (TNF-α and IL-1β) and anti-pro-inflammator cytokines (IL-10 and IL-4) increase in brain after status epilepticus (). It is reported that abnormally activated microglia, such as stimulated by LPS or kainic acid (KA), aggravate nervous system injury by secreting a variety of pro-inflammatory factors, including IL-1β, IL-12, and TNF-α (; ). However, stimulated by specific drugs or cytokines induce microglia to secrete anti-inflammatory factors or express specific genes, such as IL-10, Arg1, which are involved in promoting nerve repair and neurogenesis (; ). This regulation of microglia has been observed in several brain diseases such as Alzheimer’s Disease (; ), ischemia (; ), and sclerosis (; ; ; ; ). It has been shown that pilocarpine-induced status epilepticus was associated with mixed expression of inflammatory profiles (). The present observation also showed this microglial inflammatory regulation during seizures. The pro-inflammatory markers (iNOS and COX2) were upregulated in pilocarpine-induced SE mice. We found that treatment with the novel H2S donor in SE mice decreased the expression of microglial pro-inflammatory markers in the hippocampus. Further, the H2S donor increased the levels of microglial anti-inflammatory marker Arg1. In LPS-treated microglia BV2 cells, the expression of pro-inflammatory markers (iNOS and COX2) was significantly increased. The novel H2S donor reduced the LPS-induced pro-inflammatory marker expression, while it also promoted the release of anti-inflammatory cytokines, as indicated by the increased expression of anti-inflammatory markers (Arg1 and IL-10). Since epilepsy is an inflammation-related disease, our results in vitro supported the conclusion of in vivo studies that the novel H2S donor might regulate the inflammatory of microglia. In a word, the present results indicated that the novel H2S donor not only reduced microglial pro-inflammatory profiles, but also simultaneously increased microglial anti-inflammatory profiles. Nowadays, exogenous H2S donors, in a variety of experimental systems, were found to induce the activation of signal transduction effects (such as p38, Akt, Erk, JNK, and Stat3), which in turn, produce different functional responses to the expression of various microglia surface antigens and secreted cytokines and exert anti-inflammatory effects (, ; ; ; ; ).
In conclusion, our study demonstrated that the novel H2S donor can reduce seizures and regulate microglial inflammatory profile. The novel H2S donor decreased the release of several pro-inflammatory cytokines (such as TNF-α), which may result in reduced neuronal damage. On the other hand, the H2S donor simultaneously increased the release of anti-inflammatory cytokines (such as IL-10), which may result in neuronal recovery. Collectively, our findings identify the H2S donor as a potentially approach for seizure neuroprotection.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The animal study was reviewed and approved by Institutional Animal Care and Use Committee of Guangzhou Medical University.
Author contributions
XZ and PX designed and conceptualized the experiments. ZL, ZZ, YaH, QK, FL, WZ, YuH, YL, and BH performed the experiments and analyzed the data. ZL and ZZ wrote the manuscript. XZ, PX, and MM revised the manuscript. All authors have read and approved the final manuscript.
Funding
This work was supported by grants from National Natural Science Foundation of China (82071444, 82071416, 82171240, 81870992 and 81870856) and Natural Science Foundation of Guangdong Province of China (2020A1515010985).
Acknowledgments
We gratefully acknowledge the dedicated efforts of the investigators and the coordinators who participated in this study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AloisiF. (1999). The role of microglia and astrocytes in CNS immune surveillance and immunopathology.Adv. Exp. Med. Biol.468123–133. 10.1007/978-1-4615-4685-6_10
2
BaeS. K.HeoC. H.ChoiD. J.SenD.JoeE. H.ChoB. R.et al (2013). A ratiometric two-photon fluorescent probe reveals reduction in mitochondrial H2S production in Parkinson’s disease gene knockout astrocytes.J. Am. Chem. Soc.1359915–9923. 10.1021/ja404004v
3
BensonM. J.ManzaneroS.BorgesK. (2015). Complex alterations in microglial M1/M2 markers during the development of epilepsy in two mouse models.Epilepsia56895–905. 10.1111/epi.12960
4
CaoL.CaoX.ZhouY.NagpureB. V.WuZ. Y.HuL. F.et al (2018). Hydrogen sulfide inhibits ATP-induced neuroinflammation and Abeta1-42 synthesis by suppressing the activation of STAT3 and cathepsin S.Brain Behav. Immun.73603–614. 10.1016/j.bbi.2018.07.005
5
CastelblancoM.LugrinJ.EhirchiouD.NasiS.IshiiI.SoA.et al (2018). Hydrogen sulfide inhibits NLRP3 inflammasome activation and reduces cytokine production both in vitro and in a mouse model of inflammation.J. Biol. Chem.2932546–2557. 10.1074/jbc.M117.806869
6
ChenW. L.NiuY. Y.JiangW. Z.TangH. L.ZhangC.XiaQ. M.et al (2015). Neuroprotective effects of hydrogen sulfide and the underlying signaling pathways.Rev. Neurosci.26129–142. 10.1515/revneuro-2014-0051
7
DuC.JinM.HongY.LiQ.WangX. H.XuJ. M.et al (2014). Downregulation of cystathionine beta-synthase/hydrogen sulfide contributes to rotenone-induced microglia polarization toward M1 type.Biochem. Biophys. Res. Commun.451239–245. 10.1016/j.bbrc.2014.07.107
8
EyoU. B.MuruganM.WuL. J. (2017). Microglia-Neuron Communication in Epilepsy.Glia655–18. 10.1002/glia.23006
9
FengL.MuruganM.BoscoD. B.LiuY.PengJ.WorrellG. A.et al (2019). Microglial proliferation and monocyte infiltration contribute to microgliosis following status epilepticus.Glia671434–1448. 10.1002/glia.23616
10
FrielerR. A.MengH.DuanS. Z.BergerS.SchutzG.HeY.et al (2011). Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia.Stroke42179–185. 10.1161/STROKEAHA.110.598441
11
GiulianiD.OttaniA.ZaffeD.GalantucciM.StrinatiF.LodiR.et al (2013). Hydrogen sulfide slows down progression of experimental Alzheimer’s disease by targeting multiple pathophysiological mechanisms.Neurobiol. Learn. Mem.10482–91. 10.1016/j.nlm.2013.05.006
12
GordonS. (2003). Alternative activation of macrophages.Nat. Rev. Immunol.323–35. 10.1038/nri978
13
HanY.QinJ.ChangX.YangZ.BuD.DuJ. (2005). Modulating effect of hydrogen sulfide on gamma-aminobutyric acid B receptor in recurrent febrile seizures in rats.Neurosci. Res.53216–219. 10.1016/j.neures.2005.07.002
14
HenkelJ. S.BeersD. R.ZhaoW.AppelS. H. (2009). Microglia in ALS: the good, the bad, and the resting.J. Neuroimmune Pharmacol.4389–398. 10.1007/s11481-009-9171-5
15
HiragiT.IkegayaY.KoyamaR. (2018). Microglia after Seizures and in Epilepsy.Cells7:26. 10.3390/cells7040026
16
HuL. F.LuM.Hon WongP. T.BianJ. S. (2011). Hydrogen sulfide: neurophysiology and neuropathology.Antioxid. Redox Signal.15405–419. 10.1089/ars.2010.3517
17
HuX.LeakR. K.ShiY.SuenagaJ.GaoY.ZhengP.et al (2015). Microglial and macrophage polarization-new prospects for brain repair.Nat. Rev. Neurol.1156–64. 10.1038/nrneurol.2014.207
18
HuX.LiP.GuoY.WangH.LeakR. K.ChenS.et al (2012). Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia.Stroke433063–3070. 10.1161/STROKEAHA.112.659656
19
HuangC. W.FengW.PehM. T.PehK.DymockB. W.MooreP. K. (2016). A novel slow-releasing hydrogen sulfide donor, FW1256, exerts anti-inflammatory effects in mouse macrophages and in vivo.Pharmacol. Res.113533–546. 10.1016/j.phrs.2016.09.032
20
KolluruG. K.ShenX.BirS. C.KevilC. G. (2013). Hydrogen sulfide chemical biology: pathophysiological roles and detection.Nitric Oxide355–20. 10.1016/j.niox.2013.07.002
21
KumarM.AroraP.SandhirR. (2021). Hydrogen Sulfide Reverses LPS-Induced Behavioral Deficits by Suppressing Microglial Activation and Promoting M2 Polarization.J. Neuroimmune Pharmacol.16483–499. 10.1007/s11481-020-09920-z
22
KwanP.ArzimanoglouA.BergA. T.BrodieM. J.Allen HauserW.MathernG.et al (2010). Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.Epilepsia511069–1077. 10.1111/j.1528-1167.2009.02397.x
23
LeeM.McGeerE. G.McGeerP. L. (2016). Sodium thiosulfate attenuates glial-mediated neuroinflammation in degenerative neurological diseases.J. Neuroinflammation13:32. 10.1186/s12974-016-0488-8
24
LeeM.SparatoreA.Del SoldatoP.McGeerE.McGeerP. L. (2010). Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation.Glia58103–113. 10.1002/glia.20905
25
LiL.Salto-TellezM.TanC. H.WhitemanM.MooreP. K. (2009). GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat.Free Radic Biol Med47103–113. 10.1016/j.freeradbiomed.2009.04.014
26
LiY. F.XiaoC. S.HuiR. T. (2009). Calcium sulfide (CaS), a donor of hydrogen sulfide (H(2)S): a new antihypertensive drug?.Med. Hypotheses73445–447. 10.1016/j.mehy.2009.03.030
27
LiL.WhitemanM.GuanY. Y.NeoK. L.ChengY.LeeS. W.et al (2008). Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide.Circulation1172351–2360. 10.1161/CIRCULATIONAHA.107.753467
28
LiY.WangH. J.WangX. Z.LiX. L.ZhangX.LiuH. (2020). Effect of Hydrogen Sulfide on the Mitogen-Activated Protein Kinase Signaling Pathway in Cultured Skin Macrophages of Burned Rats.J. Surg. Res.245467–474. 10.1016/j.jss.2019.07.092
29
LiaoB.ZhaoW.BeersD. R.HenkelJ. S.AppelS. H. (2012). Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS.Exp. Neurol.237147–152. 10.1016/j.expneurol.2012.06.011
30
LiuD.ZhuZ.DuS.ChenP.GuoM.ZhangY.et al (2021). A novle hydrogen sulfide donor modulates Kir6.2 via the cyclic guanosine monophosphatedependent protein kinase signaling pathway in one side hippocampus of epileptic rats.Chin. J. Neurol.54242–250.
31
LuoY.WuP. F.ZhouJ.XiaoW.HeJ. G.GuanX. L.et al (2014). Aggravation of seizure-like events by hydrogen sulfide: involvement of multiple targets that control neuronal excitability.CNS Neurosci. Ther.20411–419. 10.1111/cns.12228
32
MelloL. E.CovolanL. (1996). Spontaneous seizures preferentially injure interneurons in the pilocarpine model of chronic spontaneous seizures.Epilepsy Res.26123–129. 10.1016/s0920-1211(96)00048-4
33
MikitaJ.Dubourdieu-CassagnoN.DeloireM. S.VekrisA.BiranM.RaffardG.et al (2011). Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration.Mult. Scler.172–15. 10.1177/1352458510379243
34
MoM.EyoU. B.XieM.PengJ.BoscoD. B.UmpierreA. D.et al (2019). Microglial P2Y12 Receptor Regulates Seizure-Induced Neurogenesis and Immature Neuronal Projections.J. Neurosci.399453–9464. 10.1523/JNEUROSCI.0487-19.2019
35
NagpureB. V.BianJ. S. (2015). Brain, Learning, and Memory: role of H2S in Neurodegenerative Diseases.Handb. Exp. Pharmacol.230193–215. 10.1007/978-3-319-18144-8_10
36
OrihuelaR.McPhersonC. A.HarryG. J. (2016). Microglial M1/M2 polarization and metabolic states.Br. J. Pharmacol.173649–665. 10.1111/bph.13139
37
PaulB. D.SnyderS. H. (2014). Neurodegeneration in Huntington’s disease involves loss of cystathionine gamma-lyase.Cell Cycle132491–2493. 10.4161/15384101.2014.950538
38
PeferoenL. A.VogelD. Y.UmmenthumK.BreurM.HeijnenP. D.GerritsenW. H.et al (2015). Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis.J. Neuropathol. Exp. Neurol.7448–63. 10.1097/NEN.0000000000000149
39
SantosL. E.BeckmanD.FerreiraS. T. (2016). Microglial dysfunction connects depression and Alzheimer’s disease.Brain Behav. Immun.55151–165. 10.1016/j.bbi.2015.11.011
40
SulenA.GullaksenS. E.BaderL.McClymontD. W.SkavlandJ.GavassoS.et al (2016). Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells.Pharmacol. Res.113216–227. 10.1016/j.phrs.2016.08.018
41
TanB. H.WongP. T.BianJ. S. (2010). Hydrogen sulfide: a novel signaling molecule in the central nervous system.Neurochem. Int.563–10. 10.1016/j.neuint.2009.08.008
42
TangY.LeW. (2016). Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases.Mol. Neurobiol.531181–1194. 10.1007/s12035-014-9070-5
43
TherajaranP.HamiltonJ. A.O’BrienT. J.JonesN. C.AliI. (2020). Microglial polarization in posttraumatic epilepsy: potential mechanism and treatment opportunity.Epilepsia61203–215. 10.1111/epi.16424
44
ThijsR. D.SurgesR.O’BrienT. J.SanderJ. W. (2019). Epilepsy in adults.Lancet393689–701. 10.1016/S0140-6736(18)32596-0
45
UludagI. F.BilginS.ZorluY.TunaG.KirkaliG. (2013). Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures.Seizure22457–461. 10.1016/j.seizure.2013.03.004
46
VandiverM.SnyderS. H. (2012). Hydrogen sulfide: a gasotransmitter of clinical relevance.J. Mol. Med.90255–263. 10.1007/s00109-012-0873-4
47
VarnumM. M.IkezuT. (2012). The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer’s disease brain.Arch. Immunol. Ther. Exp.60251–266. 10.1007/s00005-012-0181-2
48
VezzaniA. (2004). Brain Inflammation and Seizures.Epilepsy Curr.473–75. 10.1111/j.1535-7597.2004.42012.x
49
VezzaniA.AronicaE.MazaratiA.PittmanQ. J. (2013). Epilepsy and brain inflammation.Exp. Neurol.24411–21. 10.1016/j.expneurol.2011.09.033
50
VezzaniA.BalossoS.RavizzaT. (2019). Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy.Nat. Rev. Neurol.15459–472. 10.1038/s41582-019-0217-x
51
VezzaniA.FrenchJ.BartfaiT.BaramT. Z. (2011). The role of inflammation in epilepsy.Nat. Rev. Neurol.731–40. 10.1038/nrneurol.2010.178
52
VezzaniA.LangB.AronicaE. (2015). Immunity and Inflammation in Epilepsy.Cold Spring Harb. Perspect. Med.6:a022699. 10.1101/cshperspect.a022699
53
VogelD. Y.VereykenE. J.GlimJ. E.HeijnenP. D.MoetonM.van der ValkP.et al (2013). Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status.J. Neuroinflammation10:35. 10.1186/1742-2094-10-35
54
WangM.ChenY. (2018). Inflammation: a Network in the Pathogenesis of Status Epilepticus.Front. Mol. Neurosci.11:341. 10.3389/fnmol.2018.00341
55
WangR. (2012). Physiological implications of hydrogen sulfide: a whiff exploration that blossomed.Physiol. Rev.92791–896. 10.1152/physrev.00017.2011
56
WebsterK. M.SunM.CrackP.O’BrienT. J.ShultzS. R.SempleB. D. (2017). Inflammation in epileptogenesis after traumatic brain injury.J. Neuroinflammation14:10. 10.1186/s12974-016-0786-1
57
YangC. T.Devarie-BaezN. O.HamsathA.FuX. D.XianM. (2020). S-Persulfidation: chemistry, Chemical Biology, and Significance in Health and Disease.Antioxid. Redox Signal.331092–1114. 10.1089/ars.2019.7889
58
YangX.XuS.QianY.XiaoQ. (2017). Resveratrol regulates microglia M1/M2 polarization via PGC-1alpha in conditions of neuroinflammatory injury.Brain Behav. Immun.64162–172. 10.1016/j.bbi.2017.03.003
59
ZhangJ.RongP.ZhangL.HeH.ZhouT.FanY.et al (2021). IL4-driven microglia modulate stress resilience through BDNF-dependent neurogenesis.Sci. Adv.7:eabb9888. 10.1126/sciadv.abb9888
60
ZhangM.WuX.XuY.HeM.YangJ.LiJ.et al (2017). The cystathionine beta-synthase/hydrogen sulfide pathway contributes to microglia-mediated neuroinflammation following cerebral ischemia.Brain Behav. Immun.66332–346. 10.1016/j.bbi.2017.07.156
61
ZhuX.HeY.LiuZ.ZhuZ.HeY.QiuJ.et al (2020). A novel carbazole-based hydrogen-sulfide donor suppresses seizures and upregulates ATP-sensitive potassium channels.Appl. Mater. Today19:100559. 10.1016/j.apmt.2020.100559
62
ZhuZ.HeY.LiuZ.ZhangW.KangQ.LinY.et al (2021). A hydrogen sulfide donor suppresses pentylenetetrazol-induced seizures in rats via PKC signaling.Eur. J. Pharmacol.898:173959. 10.1016/j.ejphar.2021.173959
Summary
Keywords
hydrogen sulfide donor, status epilepticus (SE), inflammatory profile, neuroinflammation, pilocarpine
Citation
Liu Z, Zhu Z, He Y, Kang Q, Li F, Zhang W, He Y, Lin Y, Huang B, Mo M, Xu P and Zhu X (2021) A Novel Hydrogen Sulfide Donor Reduces Pilocarpine-Induced Status Epilepticus and Regulates Microglial Inflammatory Profile. Front. Cell. Neurosci. 15:780447. doi: 10.3389/fncel.2021.780447
Received
21 September 2021
Accepted
25 October 2021
Published
02 December 2021
Volume
15 - 2021
Edited by
Bi-Wen Peng, Wuhan University, China
Reviewed by
Giulia Albertini, INSERM U839 Institut du Fer à Moulin (IFM), France; Barbara Monti, University of Bologna, Italy
Updates
Copyright
© 2021 Liu, Zhu, He, Kang, Li, Zhang, He, Lin, Huang, Mo, Xu and Zhu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiaoqin Zhu, whzhuxiaoqin@163.comPingyi Xu, pingyixu@sina.com
†These authors have contributed equally to this work
This article was submitted to Non-Neuronal Cells, a section of the journal Frontiers in Cellular Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.